The FLUID trial was designed to fill in the evidence for all the patients in between the ED and intensive care unit (ICU), as ...

HHS Secretary Robert F. Kennedy Jr. announced his decision to "retire" all 17 members of the CDC's Advisory Committee on ...

Note that some links may require registration or subscription. The United Kingdom's Food Standards Agency says that certain ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn.

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

The study cohort had a median age around 60, with about 20% women and a median BMI of 26. Nearly 80% were white and the rest ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

CHICAGO -- Bobby Mukkamala, MD, credits NIH-funded research for the targeted therapy that keeps his brain tumor at bay. But ...